Cardiac electrophysiology

BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services

Retrieved on: 
Tuesday, March 29, 2022
Online, Company, Electrophysiology, Journal, PURE, Saint David, Journal of Cardiovascular Electrophysiology, Partnership, Cardiac electrophysiology, ECG, Risk, Medical Center, Massachusetts General Hospital, Summit, Wiley (publisher), SEC, Program, Decision-making, CEO, U.S. Securities and Exchange Commission, United, EP, Mayo Clinic, Technology, Friction, Nasdaq, COVID-19, GLOBE, Physician, St Davids, Solution, Nautilus, Inc. v. Biosig Instruments, Inc., Annual report, FDA, Patient, Security (finance), Pharmaceutical industry

The Minneapolis-based Summit Blue Capital is a leader in equipment finance and leasing.

Key Points: 
  • The Minneapolis-based Summit Blue Capital is a leader in equipment finance and leasing.
  • Most notably, Summit Blue Capital specializes in simplifying the financing experience and finding solutions to advance commercial roll outs in the healthcare industry.
  • "We believe that partnering with Summit Blue Capital will have considerable benefits to our commercial plans.
  • The team at Summit Blue Capital is expected to also help us launch a subscription-based revenue model for our software.

BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer

Retrieved on: 
Wednesday, March 16, 2022
Online, Abbott, SEC, Decision-making, PURE, CALA, Solution, Risk, GLOBE, Annual report, Johns Hopkins University, Patient, Electrophysiology, Hospital, FDA, Nasdaq, Massachusetts General Hospital, COVID-19, St Davids, EP, Biomedical engineering, Nautilus, Inc. v. Biosig Instruments, Inc., Senior, ABT, Wiley (publisher), Security (finance), Saint David, Journal, ECG, Medical Center, Company, St. Jude Medical, Mayo Clinic, General officer, CEO, Arrhythmia, Abbott Laboratories, NYSE, Biomedicine, Physician, U.S. Securities and Exchange Commission, Journal of Cardiovascular Electrophysiology, Cardiac electrophysiology, Pharmaceutical industry

Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer.

Key Points: 
  • Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer.
  • Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories [NYSE: ABT].
  • Mr. Sieckhaus holds a Bachelor of Science degree in Biomedical Engineering from Johns Hopkins University.
  • Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov.

Implicity Hosts US Research Competition for Free Access to Advanced AI-powered Cardiac Remote Monitoring Platform

Retrieved on: 
Thursday, March 10, 2022
Heart, Industry, Degenerative disease, Physician, Research, Cardiac electrophysiology, ILR, RM, Academic health science centre, ENG, Health, Adoption, Arrhythmia, CI, Doctor of Philosophy, Patient, Fortis Healthcare, Solution, CEO, Diagnosis, Algorithm, Medical device, IEEE Society on Social Implications of Technology

CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Implicity , a leader in AI-powered remote patient monitoring and cardiac data management solutions, today announced an invitation for US-based researchers who are looking to conduct a study in the field of Cardiac Rhythm Management to apply for free access to Implicity's cardiac remote monitoring software, including the ILR ECG Analyzer & Advanced Research Tool.

Key Points: 
  • CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Implicity , a leader in AI-powered remote patient monitoring and cardiac data management solutions, today announced an invitation for US-based researchers who are looking to conduct a study in the field of Cardiac Rhythm Management to apply for free access to Implicity's cardiac remote monitoring software, including the ILR ECG Analyzer & Advanced Research Tool.
  • "Research is at the heart of what we do at Implicity.
  • Cardiac remote monitoring has already been shown to reduce the number of unnecessary emergency department visits and improve the time to diagnose clinical events.
  • Winners receive free access to Implicity's AI-powered Cardiac Remote Monitoring platform and features, including the ILR ECG Analyzer and the Advanced Research Tool module, for a minimum of 12 months.

Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial

Retrieved on: 
Monday, February 7, 2022
People, Department, Time, Cleveland Clinic, Metal electrode leadless face, Heart, Heart rate, PMID, Technology, Patient, NYSE, Parenteral nutrition, Lead, Life, Health, Physician, DDD, Muscle tissue, Cardiac electrophysiology, Communication, Associate, Medical device, Medical imaging, Electrophysiology, Cardiology

People who experience a slower-than-normal heart rate may receive a pacemaker -- a small battery-powered device implanted in the chest that delivers electrical impulses via thin insulated wires, called cardiac leads, that cause the heart muscle chambers to contract to help restore a normal heart rhythm. Unlike traditional pacemakers, leadless pacemakers are implanted directly into the heart through a minimally invasive catheter-based procedure and eliminate the need for cardiac leads. While leadless pacemakers work like traditional pacemakers to regulate heart rate, they offer reduced lead-related complications and a less restrictive recovery period due to the minimally invasive implant procedure.i Yet historically, leadless pacing options have been limited to single-chamber devices because synchronization of two leadless pacemakers has been highly difficult to achieve.

Key Points: 
  • ABBOTT PARK, Ill., Feb. 7, 2022 /PRNewswire/ --Abbott (NYSE: ABT) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study.
  • The implant of Abbott's investigational Aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial.
  • The latest milestone for the Aveir DR leadless pacemaker follows recent data showing that Abbott's investigational single-chamber leadless pacemaker Aveir VR met the pre-specified primary endpoints in its pivotal trial.
  • Abbott also designed the Aveir DR leadless pacemaker to be retrievable, so the system can be replaced or retrieved as therapy needs evolve.

Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial

Retrieved on: 
Monday, February 7, 2022
People, Department, Time, Cleveland Clinic, Metal electrode leadless face, Heart, Heart rate, PMID, Technology, Patient, NYSE, Parenteral nutrition, Lead, Life, Health, Physician, DDD, Muscle tissue, Cardiac electrophysiology, Communication, Associate, Medical device, Medical imaging, Electrophysiology, Cardiology

ABBOTT PARK, Ill., Feb. 7, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i™ pivotal clinical study. The implant of Abbott's investigational Aveir™ dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial.

Key Points: 
  • The implant of Abbott's investigational Aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial.
  • Abbott has focused significantly on driving leadless pacing technology that can potentially improve care for more patients battling abnormal heart rhythms.
  • The latest milestone for the Aveir DR leadless pacemaker follows recent data showing that Abbott's investigational single-chamber leadless pacemaker Aveir VR met the pre-specified primary endpoints in its pivotal trial.
  • Abbott also designed the Aveir DR leadless pacemaker to be retrievable, so the system can be replaced or retrieved as therapy needs evolve.

Philips supports the American Heart Association’s efforts to raise awareness of cardiovascular implantable electronic device (CIED) infections, promote guideline adherence, and improve patient survival rates

Retrieved on: 
Wednesday, January 19, 2022
Narrative, Dai, American Heart Association, Patient, Electrophysiology, Mortality, Disease, NYSE, Senior, Diagnosis, Veni, vidi, vici, Heart Rhythm Society, Completeness, Â, AHA, AIFF Elite Academy, Incidence, PHG, Infection, AEX, Lead, Education, Epidemiology, Journal of the American College of Cardiology, American Heart, Guideline, Risk, Treatment, Anguera, Cardiac electrophysiology, Internal medicine, Awareness, Pharmaceutical industry, Medical device, Greenspan

Clinical practice guidelines recommend extraction for all patients with a definite CIED infection, including complete device and lead removal.

Key Points: 
  • Clinical practice guidelines recommend extraction for all patients with a definite CIED infection, including complete device and lead removal.
  • Too often, healthcare professionals lack awareness and experience in CIED infection management, increasing the chance of a missed infection diagnosis and prolonging inappropriate treatment.
  • It is estimated that in the USA more than 7,000 CIED patient lives are at risk each year due to improper treatment.
  • These efforts amplify the mission of the American Heart Association to help every person have the opportunity for a longer, healthier life.

H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.

Retrieved on: 
Tuesday, January 11, 2022
Catheter, Technology, Letter, SEC, Risk, FDA, Arrhythmia, Cardiac electrophysiology, GLOBE, OTCQB, Acquisition, Medical device

Catheter Precision has developed two cost-effective, user friendly and advanced technologies to improve the treatment of cardiac arrhythmias.

Key Points: 
  • Catheter Precision has developed two cost-effective, user friendly and advanced technologies to improve the treatment of cardiac arrhythmias.
  • These healthcare devices include ground-breaking robotic and technologic solutions to bring new opportunities to market for complex medical procedures.
  • The company includes an experienced and successful board of directors, group of scientific advisors and management team.
  • H-CYTEs mission is to become a leader in next generation medical technology with the ultimate goal of improving patient lives.

BioSig to Present at the 24th Annual Virtual Needham Growth Conference

Retrieved on: 
Thursday, January 6, 2022
Online, Mayo Clinic, Atrial fibrillation, ST, COVID-19, University, Wiley (publisher), Company, Patient, Physician, Journal, Cardiac electrophysiology, Risk, Journal of Cardiovascular Electrophysiology, U.S. Securities and Exchange Commission, Conference, Electrophysiology, Security (finance), ECG, Scripps Health, Decision-making, Massachusetts General Hospital, SEC, Arrhythmia, Health, FDA, Korea Disease Control and Prevention Agency, University of Pennsylvania, GLOBE, Technology, Nasdaq, Nautilus, Inc. v. Biosig Instruments, Inc., PURE, Center, Needham, CDC, Medical device

Westport, CT, Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it it will present at the 24th Annual Virtual Needham Growth Conference on Friday, January 14th , 2022 at 4:15 PM ET.

Key Points: 
  • Westport, CT, Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it it will present at the 24th Annual Virtual Needham Growth Conference on Friday, January 14th , 2022 at 4:15 PM ET.
  • For parties interested in scheduling a one-on-one meeting with BioSig management, please contact your Needham representative.
  • The PURE EP is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

BioSig Technologies, Inc. Selects Access Strategy Partners to Accelerate Commercial Sales

Retrieved on: 
Tuesday, December 21, 2021
Online, Time-invariant system, PURE, GLOBE, Organization, Learning, FDA, Wiley (publisher), Decision-making, Mayo Clinic, Physician, Purchasing, CEO, Journal, Marketing, Electrophysiology, Security (finance), ECG, U.S. Securities and Exchange Commission, Risk, COVID-19, Boston Scientific, Nasdaq, Nautilus, Inc. v. Biosig Instruments, Inc., National, Intelligence, Innovation, Abbott, EP, Internationalized domain name, Cardiac electrophysiology, BSC, Company, SEC, Journal of Cardiovascular Electrophysiology, Clinical professor, Massachusetts General Hospital, Patient, Johnson & Johnson, Medical device, Risk management, Pharmaceutical industry

Led by medical device sales experts, Boston-based Access Strategy Partners brings to BioSig deep expertise in commercialization, contract management, execution, and value proposition optimization.

Key Points: 
  • Led by medical device sales experts, Boston-based Access Strategy Partners brings to BioSig deep expertise in commercialization, contract management, execution, and value proposition optimization.
  • Under the terms of the new collaboration, Access Strategy Partners will advise BioSig on all aspects of commercial strategy, including economic value modeling, hospital administration engagement, and contracting.
  • Jim and his highly accomplished team at Access Strategy Partners brings us proven success strategies in accelerating commercialization.
  • The Company recently appointed a former Abbott senior sales leader Mr. Gray Fleming as its Chief Commercial Officer.

First U.S. patients with persistent cardiac arrythmias treated using Volta Medical’s artificial intelligence-based analysis

Retrieved on: 
Tuesday, December 21, 2021
Northwell Health, GLOBE, CE, Tailor, Burn, FDA, Entrepreneurship, Lenox Hill Hospital, Union, Artificial intelligence, Hospital, Heart failure, Paola Lattus, AF, Palpitations, Physician, Arrhythmia, CEO, Medicine, Lightheadedness, Stroke, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AAD, Blood, Safety, Risk, Atrial tachycardia, Cardiology, AI, Weill Cornell Medicine, AT, Cardiac electrophysiology, Intuition, PVI, Atrial fibrillation, Food, Heart, New, Ascension St. Mary's Hospital, Patient, Trial of the century, Medical device, Medical imaging, Pharmaceutical industry, Novel, MD

VX1 is cleared as a medical device by the U.S. Food and Drug Administration and CE-certified by the European Union.

Key Points: 
  • VX1 is cleared as a medical device by the U.S. Food and Drug Administration and CE-certified by the European Union.
  • VX1 is the first commercially available AI software to help clinicians combat high failure rates in the use of ablation for treating persistent, drug-resistant AF.
  • With 50% of persistent AF patients requiring repeat treatments,7 the need for more precise therapies is significant.
  • Volta Medical is a health tech company developing AI software solutions to assist cardiac electrophysiologists in the operating room.